Search results for "Immune System Diseases"

showing 10 items of 442 documents

Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.

2019

Itch is the most bothersome symptom in psoriasis, often leading to impaired quality of life. Treatment of psoriasis-induced itch is frequently unsatisfactory as the various therapies employed have a delayed onset of effect. Histamine-1 receptor (H1) antihistamines are not recommended in treatment guidelines as histamine is not considered a key mediator in psoriasis. However, patients using H1 antihistamines frequently report benefits in questionnaire-based studies. To address these contradictions, we examined the short-term effects of levocetirizine, a nonsedating H1 antihistamine, on psoriasis-related itch and itch-related quality of life. In this pilot study, patients with psoriasis-relat…

AdultMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingTime FactorsPilot ProjectsDermatologyLevocetirizine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesPsoriasisparasitic diseasesotorhinolaryngologic diseasesMedicineEffective treatmentHumansPsoriasisskin and connective tissue diseasesH1 antihistamineDose-Response Relationship Drugbusiness.industryPruritusDelayed onsetGeneral MedicineMiddle Agedmedicine.diseaseDermatologyeye diseasesCetirizineTreatment Outcome030220 oncology & carcinogenesisConcomitantQuality of LifeFemaleOpen labelbusinessmedicine.drugDermatologic therapyREFERENCES
researchProduct

Risk of Non-Hodgkin Lymphoma in Celiac Disease

2002

CONTEXT: Celiac disease is one of the most common lifelong disorders. Non-Hodgkin lymphoma is a possible complication of celiac disease and may lead to a large portion of lymphoma cases. OBJECTIVE: To quantify the risk for developing non-Hodgkin lymphoma of any primary site associated with celiac disease. DESIGN AND SETTING: Multicenter, case-control study conducted between January 1996 and December 1999 throughout Italy. PATIENTS: Cases were older than 20 years (median, 57; range, 20-92 years) with non-Hodgkin lymphoma of any primary site and histological type and were recruited at the time of the diagnosis. Controls were healthy adults (2739 men and 2981 women) from the general population…

AdultMalemedicine.medical_specialtyPathologyLymphoma B-CellSettore MED/09 - Medicina InternaPopulationLymphoma T-CellNon-Hodgkin lymphoma; celiac diseaseGastroenterologyCoeliac diseaseRisk Factorsimmune system diseaseshemic and lymphatic diseasesInternal medicineImmunopathologymedicineHumansT-cell lymphomaNon-hodgkin diseaseeducationMass screeningAgedNon-Hodgkin lymphomaAged 80 and overeducation.field_of_studybusiness.industryLymphoma Non-HodgkinCase-control studyGeneral MedicineOdds ratioMiddle Agedmedicine.diseaseLymphomaCase-Control StudiesFemalebusinessceliac diseaseJAMA
researchProduct

Controversies and challenges in the management of chronic urticaria

2016

This supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Despite the clear international guideline, there remain a number of controversies and challenges in the management of patients with chronic urticaria (CU). As a result of major advancements in urticaria over the past 4 years, the current EAACI/GA(2) LEN/EDF/WAO urticaria guideline treatment algorithm requires updating. Case studies from patients with chronic spontaneous urticaria (CSU) [also called chronic idiopathic urticaria (CIU)], chronic inducible urticaria (CIndU) or diseases and syndromes related to CU are useful in describing and exploring chall…

AdultMalemedicine.medical_specialtyPathologyUrticariaAlternative medicineDermatologyUnmet needs030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineimmune system diseasesparasitic diseasesmedicineHumansAngioedemaDisease management (health)ChildIntensive care medicineskin and connective tissue diseasesChronic urticariaAgedbusiness.industryGuidelineMiddle AgedPedigreeCold TemperatureInfectious Diseases030228 respiratory systemChronic DiseaseHistamine H1 AntagonistsSunlightFemaleChronic idiopathic urticariabusiness
researchProduct

Development and validation of the Urticaria Control Test: a patient-reported outcome instrument for assessing urticaria control.

2013

Background Chronic urticaria is a frequent and debilitating skin disease. Its symptoms commonly fluctuate considerably from day to day. As of yet, the only reliable tool to assess disease activity is the Urticaria Activity Score, which prospectively documents the signs and symptoms of urticaria for several days. Objective We sought to develop and validate a novel patient-reported outcome instrument to retrospectively assess urticaria control, the Urticaria Control Test (UCT). Methods Potential UCT items were developed by using established methods (literature research and expert and patient involvement). Subsequently, item reduction was performed by using a combined approach, applying impact…

AdultMalemedicine.medical_specialtyPediatricsAdolescentUrticariaVisual analogue scaleIntraclass correlationImmunologyMEDLINEDiseaseimmune system diseasesGermanyparasitic diseasesImmunology and AllergyMedicineHumansskin and connective tissue diseasesAgedRetrospective StudiesAged 80 and overReceiver operating characteristicbusiness.industryRetrospective cohort studyMiddle AgedControl testPhysical therapyPatient-reported outcomeFemalebusinessThe Journal of allergy and clinical immunology
researchProduct

Burkitt lymphoma associated with human immunodeficiency virus infection and pulmonary tuberculosis: A case report.

2019

Abstract Introduction: The association of human immunodeficiency virus (HIV) infection with Burkitt lymphoma is related to the presence of Epstein Barr virus infection and the impact of the HIV antigen on the expansion of B-polyclonal cells. In Southeast Europe, the association is rare, and recognizing this is important in the therapeutic decision to increase patient survival rate. The association of HIV with Burkitt lymphoma and tuberculosis is even more rarely described in the literature. Patient concerns: We present the case of a 40-year-old patient who presented with a 3-week history of fever (max. 38.7 °C), painful axillary swelling on the right side, lumbar pain, gait disorders, heada…

AdultMalemedicine.medical_specialtyTuberculosisAntitubercular AgentsAntineoplastic AgentsHIV Infectionshuman immunodeficiency virus infectionNeurosurgical ProceduresMycobacterium tuberculosis03 medical and health sciences0302 clinical medicinePharmacotherapyFatal Outcomeimmune system diseasesInternal medicinehemic and lymphatic diseasesAntiretroviral Therapy Highly ActivemedicineHumans030212 general & internal medicineClinical Case ReportEpstein–Barr virus infectionTuberculosis PulmonaryImmunodeficiencydose-adjusted etoposide doxorubicin and cyclophosphamide with vincristine prednisone and rituximabbiologyClinical Deteriorationbusiness.industry4900BrainBurkitt lymphomaGeneral MedicineViral Loadhighly active antiretroviral therapymedicine.diseasebiology.organism_classificationDecompression SurgicalLymphomaCD4 Lymphocyte CountSpinal Cord030220 oncology & carcinogenesisSputummedicine.symptombusinessViral loadpulmonary tuberculosisResearch ArticleMedicine
researchProduct

The Urticaria Activity Score-Validity, Reliability, and Responsiveness.

2018

Background Chronic spontaneous urticaria is characterized by fluctuating symptoms. Its activity is assessed with the urticaria activity score (UAS). Two versions of the urticaria activity score used for 7 consecutive days (UAS7) are available: (1) The guideline-recommended UAS7, with once-daily documentation, and (2) the UAS7TD, with twice-daily documentation. Objective To better characterize both UAS7 versions with regard to their validity, reliability, sensitivity to change, minimal important difference (MID), and smallest detectable change (SDC). Methods One hundred thirty adult patients with chronic spontaneous urticaria completed both UAS7 versions, the Patients Global Assessment (PatG…

AdultMalemedicine.medical_specialtyUrticariaIntraclass correlationOmalizumabOmalizumabSeverity of Illness IndexDisease activity030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesInternal medicineAnti-Allergic AgentsImmunology and AllergyMedicineHumansskin and connective tissue diseasesReceiver operating characteristicbusiness.industryReproducibility of ResultsDermatology Life Quality IndexMiddle AgedStandard error030228 respiratory systemChronic DiseasePhysical therapyPatient-reported outcomeFemalebusinessmedicine.drugThe journal of allergy and clinical immunology. In practice
researchProduct

MACOP-B chemotherapy for the treatment of high grade and intermediate grade non Hodgkin's lymphoma.

1990

Between Nov. 1985 and Nov. 1988, sixty-three patients with high grade malignant (hg) and intermediate grade malignant (img) Non Hodgkin's Lymphoma (NHL) were treated with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone and bleomycin). Thirty-seven patients received MACOP-B as an upfront treatment modality, whereas twenty-six patients had relapsed disease and received MACOP-B as a salvage protocol. Four weeks after termination of therapy, 75% of patients with de novo NHL and 72% of the patients with relapsed NHL were in complete remission (CR). In the group of newly diagnosed NHL, 22% achieved partial remission (PR) and 3% no change (NC), whereas in the group wi…

AdultMalemedicine.medical_specialtyVincristineCyclophosphamidemedicine.medical_treatmentLeucovorinSalvage therapyGastroenterologyBleomycinimmune system diseaseshemic and lymphatic diseasesInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansIntermediate GradeCyclophosphamideAgedChemotherapybusiness.industryLymphoma Non-HodgkinHematologyGeneral MedicineMiddle Agedmedicine.diseaseNon-Hodgkin's lymphomaSurgeryLymphomaMethotrexateDoxorubicinVincristinePrednisoneFemaleNeoplasm Recurrence LocalbusinessProgressive diseasemedicine.drugBlut
researchProduct

Immunologic effects of rituximab on the human spleen in immune thrombocytopenia

2011

Abstract Immune thrombocytopenia (ITP) is an autoimmune disease with a complex pathogenesis. As in many B cell–related autoimmune diseases, rituximab (RTX) has been shown to increase platelet counts in some ITP patients. From an immunologic standpoint, the mode of action of RTX and the reasons underlying its limited efficacy have yet to be elucidated. Because splenectomy is a cornerstone treatment of ITP, the immune effect of RTX on this major secondary lymphoid organ was investigated in 18 spleens removed from ITP patients who were treated or not with RTX. Spleens from ITP individuals had follicular hyperplasia consistent with secondary follicles. RTX therapy resulted in complete B-cell de…

AdultMalemedicine.medical_treatmentImmunologySplenectomySpleenT-Lymphocytes RegulatoryBiochemistryAntibodies Monoclonal Murine-DerivedImmune systemimmune system diseaseshemic and lymphatic diseasesHumansImmunologic FactorsMedicineImmunobiologyAgedAutoimmune diseaseB-LymphocytesPurpura Thrombocytopenic Idiopathicbiologybusiness.industryCell BiologyHematologyMiddle AgedTh1 Cellsmedicine.diseaseLymphatic systemmedicine.anatomical_structureImmunologyMonoclonalbiology.proteinFemaleRituximabAntibodyRituximabbusinessSpleenmedicine.drugBlood
researchProduct

Analysis of the in vitro cytokine production by liver-infiltrating T cells of patients with autoimmune hepatitis.

1993

SUMMARY The pathogenic mechanisms underlying the development of autoimmune hepatitis (AIH) are still unclear. Since AIH is associated with the presence of various autoantibodics and certain HLA subtypes, it is likely that T and B cells play a major role in this disease. In this study we have determined the functional capacities of in vivo preactivated liver-infiltrating T cells (LTC) from patients with AIH. As controls we used LTC from patients with non-autoimmune hepatitis (non-AIH). Our results show that preactivated LTC from patients with AIH predominantly (190/255 clones) reside in the CD4+ population, whereas LTC in non-AIH are dominated by the CD8+ phenotype (148/254 clones). In view …

AdultMalemedicine.medical_treatmentT cellCD8 AntigensT-LymphocytesImmunologyPopulationAutoimmune hepatitisHuman leukocyte antigenBiologyAutoimmune DiseasesHepatitisInterferon-gammaImmune systemimmune system diseasesmedicineImmunology and AllergyHumanseducationeducation.field_of_studyTumor Necrosis Factor-alphaInterleukinsMiddle Agedmedicine.diseasedigestive system diseasesClone CellsCytokinemedicine.anatomical_structureLiverImmunologyCD4 AntigensCytokinesCytokine secretionFemaleCD8Research ArticleClinical and experimental immunology
researchProduct

In Vitro Cytokine Production by HLA-B8, DR3 Positive Subjects

1994

It is well known that healthy subjects carrying the HLA-B8,DR3 haplotype may show an impairment of immune system, the T cells being the most affected. To gain insight into the mechanism(s) of the impairment displayed by these subjects, efforts have been centered on the study of in vitro cytokine production because of the pivotal role played by these mediators in the activation and control of several immune functions. The available results indicate that the ability to several immune functions. The available results indicate that the ability to produce interleukin-1 (IL-1), IL-2 and the soluble form of its receptor (sIL-2R) is impaired in HLA-B8,DR3 positive healthy subjects. To better charac…

AdultMalemusculoskeletal diseasesInterleukin 2Cellular immunitymedicine.medical_treatmentImmunologyAutoimmunityPeripheral blood mononuclear cellHLA-B8 AntigenInterferon-gammaHLA-DR3 AntigenImmune systemimmune system diseasesmedicineHumansImmunology and AllergyInterferon gammaPhytohemagglutininsInterleukin 6Cells CulturedInterleukin 4biologyInterleukin-6Receptors Interleukin-2Middle AgedRecombinant ProteinsCytokineAntibody FormationImmunologyLeukocytes Mononuclearbiology.proteinCytokinesInterleukin-2FemaleInterleukin-4medicine.drugAutoimmunity
researchProduct